Purpose Emerging EBV DNAemia in plasma is considered an early sign of post-transplant lymphoproliferative disorder (PTLD). The aim of this study was to quantify the extent of benefit from screening for EBV DNAemia to detect emerging PTLD among solid organ (SOT) or hematopoietic stem cell transplant recipients (HSCT). Methods We used receiver operating characteristic (ROC) curves for assessing ability of models to predict PTLD. Among 2642 recipients transplanted between January 2004 and December 2014, 79 (3%) developed PTLD. Results EBV DNAemia was observed in 331/1784 recipients (18.6%, 95% CI 16.8-20.4) with measured EBV DNA. The area under the curve (AUC) of the ROC of EBV DNAemia to identify persons with subsequent PTLD was 72% (95% CI, 64-79%) among SOT and 59% (51-68%) among HSCT. Including clinical predictors such as age, gender, transplant year and type, high-risk EBV serostatus, and routine biochemistry in addition to EBV DNAemia increased AUC to 83% (75-90%) among SOT and 84% (79-89%) among HSCT. Among HSCT, including additional factors such as T-cell-depleting treatment, acute graft vs. host disease and donor match increased AUC to 85% (78-91%).
Introduction
Post-transplantation lymphoproliferative disorder (PTLD) is a rare but severe and often life-threatening complication after solid organ (SOT) or hematopoietic stem cell transplantation (HSCT) (Green and Michaels 2013; Patriarca et al. 2013) . The overall mortality has been reported as high as up to 80% (Patriarca et al. 2013; Uhlin et al. 2014; Styczynski et al. 2013; Fox et al. 2014 ) depending on disease progression and transplant type.
Clinically and histologically, PTLD consists of a heterogeneous spectrum of disorders ranging from a benign proliferation of B lymphocytes to fulminant lymphoma, where the latter can resemble those seen in immunocompetent patients (Martinez and Krams 2017; Nijland et al. 2016; Ok et al. 2015) . Furthermore, PTLD is associated with Epstein-Barr virus (EBV) in the majority of the cases (Green and Michaels 2013; Ok et al. 2015) . Following diagnosis, response to currently available treatments such as chemotherapy or rituximab is often poor and the clinical strategy is thus to detect the disease at early stages and prevent progression to fulminant lymphoma (Green and Michaels 2013; Ok et al. 2015) . Detection of EBV DNA in plasma or whole blood is considered an early sign of PTLD and this biomarker is thus widely used to guide pre-emptive treatment of PTLD (Patriarca et al. 2013; Parker et al. 2010) . However, there is limited clinical evidence to support that screening for EBV DNA and detecting EBV DNAemia in an otherwise healthy transplant recipient can detect those with subsequent PTLD (Dharnidharka 2017) . Acknowledging this, current international guidelines only recommend regular screening of EBV DNA in the first year after transplantation among recipients considered as high risk of PTLD, i.e., EBV seronegative children who receive a solid organ from a seropositive donor (Parker et al. 2010 ) and HSCT treated with T-cell depleting agents or HSCT with a mismatched donor (Styczynski et al. 2009 ). Thus, since only a subgroup of patients with detectable EBV progress to develop PTLD, more precise prognostic models are required to identify those who are most likely to progress to PTLD, and thus who will most likely benefit from pre-emptive treatment.
The aim of this study was to determine the clinical utility of EBV DNAemia as a screening tool to detect emerging PTLD and furthermore to determine risk factors associated with PTLD among SOT and HSCT adults and children registered in a national transplant cohort.
Materials and methods

Study design and participants
In this retrospective cohort study we included all HSCT and SOT recipients transplanted at Rigshospitalet, Copenhagen, between January 2004 and December 2014 and registered in the MATCH cohort (Lodding et al. 2015) . This includes all liver and lung transplantations in Denmark and all HSCT, renal and heart transplantations in the eastern region of Denmark. HSCT consisted of recipients undergoing myeloablative conditioning regimens (MAC HSCT) or non-myeloablative conditioning regimens (Mini HSCT) with stem cells from related or unrelated donors and umbilical cord blood stem cells (UCB HSCT). Immunosuppressive regimens have previously been described by Ekenberg et al. (2017 ® (Argene, Biomerieux, Lyon, France) from 2015 and onward. Importantly, before changing methods, the new method was calibrated to ensure that the lower level of detection was comparable. As such, the lower limit of detection of EBV DNA was throughout the study period 500 copies/mL; detectable levels below this threshold were non-quantifiable and set to be at the lower limit of detection. The purification of EBV DNA was performed using standard methods (EasyMag, Biomerieux, Lyon, France). Cell lysis and thus, the risk of overestimating the EBV DNA load was taken into account by comparing the total genomic DNA in the plasma sample to a reference standard based on total genomic DNA measured in plasma samples from a healthy population.
Regular EBV DNA screening was scheduled in recipients considered as high risk. This was scheduled every 1-2 weeks in UCB HSCT and EBV IgG seronegative SOT recipients and less intensive in MAC HSCT during the first 6 months of follow-up. Beyond the first 6 months, intervals between screenings were gradually increased until 1 year after transplantation where the screening was terminated. Beyond the first post-transplant year, the decision of screening was based on an individual level. This was performed in the entire cohort period for HSCT whereas screening was introduced for SOT recipients in 2010-11. Prior to 2010-11 SOT recipients were screened for EBV DNA only at the discretion of the clinicians. The remaining recipients not considered as high-risk had EBV DNA measured as part of the diagnostic procedure. If EBV DNAemia was detected, the intensity of testing would increase with repeated testing on each visit and usually once a week initially. In case of stable low-copy viremia, intervals would gradually increase. Thus, EBV measurements in this cohort consisted of both screening and those performed as part of the diagnostic procedure of suspected EBV-related disease.
The clinical management of recipients with detected EBV DNAemia but no overt signs of PTLD usually included reduction of the daily doses of immunosuppression in the absence of graft rejection or graft vs. host disease (GvHD) and depending on the clinical signs and degree of viral load, pre-emptive therapy with an anti-CD20 antibody (typically rituximab) was used.
Definition and ascertainment of PTLD
The definition of PTLD was based on the WHO criteria, which require a biopsy-confirmed diagnosis (Sabattini et al. 2010 ). However, it was considered to be insufficient using only this criterion since cases treated empirically would likely not have a biopsy performed, and thus would not be captured by this definition. We, therefore, expanded the definition by including the certainty criteria "definite", "probable" and "possible" PTLD to be able to also ascertain non-biopsy-confirmed PTLDs. The ascertainment was performed through an extensive review of a variety of sources by a single trained clinician including lab data, death causes, and journal records (Online Resource 1). Rituximab use was based on prescription data including start and end dates, and was ascertained using the electronic medical records.
Statistical analysis
Factors associated with screening for EBV DNA were determined using logistic regression models.
Among those with EBV DNA screening, factors associated with a positive EBV DNA (including those measured at the lower limit of detection) were determined using Kaplan-Meier analyses and Cox proportional hazard models. Persons were left censored at first EBV DNA measurement. The model was adjusted for the time between transplant and first EBV DNA. Person follow-up was censored at the earliest of positive EBV DNA, death or last visit plus 60 days. Additional analyses investigated factors associated with an EBV DNA above the lower limit of detection, where the relationship between a positive EBV DNA at the lower limit of detection and subsequent EBV DNA above the lower limit of detection was investigated by including a positive EBV DNA at the lower limit of detection as a time-updated variable.
Kaplan-Meier analyses and Cox proportional hazard models were used to investigate factors associated with PTLD; persons were censored at PTLD, last visit plus 60 days or death, whichever occurred first. A priori, because of the likely biologic causal relationship between EBV DNAemia and PTLD, we included EBV DNAemia in all our models. Persons were classified as EBV DNA unknown until a value became available during follow-up, thus EBV DNA was included as a time-updated covariate. The EBV DNA result was lagged by 28 days to reduce the impact of EBV DNA testing in connection with clinical symptoms. AUC ROC curves were constructed to evaluate the diagnostic performance of an EBV DNAemia, again lagging the EBV DNA result by 28 days. Models were adjusted for date of transplant, age, type of transplant and number of transplants (as a time-updated covariate). ROC curves were repeated including only definite PTLD cases.
A wide range of sensitivity analyses were performed including stratification by age group and certainty of PTLD diagnosis, in SOT or HSCT and limiting analyses to after 2010 when routine screening was available for both transplant types. Furthermore, models were repeated by including information on T-cell-depleting treatment, acute GvHD and donor relation (related vs. unrelated) for HSCT. Models were also constructed including a variety of laboratory data, such as hemoglobin, leukocytes, lymphocytes, neutrocytes, thrombocytes, creatinine, alanine transaminase (ALT), albumin, C-reactive protein (CRP), and lactate dehydrogenase (LDH). Each laboratory variable was divided into quartiles and fitted as time-updated variables. The association with PTLD was tested in univariate analyses; those with a global p value < 0.1 were included in multivariate models, and categories were combined where results were similar across quartiles. All p values are two sided. A p value < 0.05 indicates statistical significance. Statistical analysis was conducted using SAS statistical software version 9.4 (SAS Institute, Cary, NC, USA).
Approvals
The research is conducted after approval of the National Data Protection Agency (2012 ( -58-0004, RH-2015 , with I-Suite number: 03787).
Results
Patient characteristics and measurement for EBV DNA
In total, 2642 consecutive adults and children underwent SOT or HSCT since January 2004 and were included in the study; these recipients were mainly males (59.8%), above 50 years of age (42.9%) and transplanted with a solid organ (74.2%). A total of 1784 (67.5%) recipients had been measured for EBV DNAemia at least once during follow-up (Fig. 1) Patient characteristics according to those with and without EBV DNA measurement are summarized in Table 1 . EBV DNA measurements were more likely to be performed among younger [adjusted odds ratio (aOR) 3.1 (95% CI 2.00-4.90)] and less likely among older recipients [0.66 (95% CI 0.51-0.87)]. As expected, persons transplanted in 2010 or later were more likely to be tested for EBV DNA than those transplanted earlier [2.4 (1.9-3.0)].
Incidence and factors associated with EBV DNAemia among those measured for EBV DNA
Among 1784 recipients measured for EBV DNA, EBV DNAemia was observed in 331 [18.6% (95% CI 16.8-20.4)] (Fig. 1) . The cumulative incidence of EBV DNAemia at 52 weeks after first measurement was 16.9% (95% CI 15.1-18.7) (Fig. 2a) . Viral loads at first measurement were mostly at the lower limit of detection (67.4%) whereas in 1 out of 10 (9.7%) viral loads at first measurement were ≥ 5000 copies/mL.
After adjustment, recipients aged ≤ 16 years were 4 times more likely to have a positive EBV DNA [adjusted hazard ratio (aHR) 4.14 (95% CI 2.89-5. . When EBV DNA was defined only as a value above the lower limit of detection, a prior positive EBV DNAemia level at the lower limit of detection was associated with over an eightfold higher rate of EBV DNAemia above the lower limit of detection compared to negative test results [8.18 (5.72-11.68) ]. Low age and type of transplant were also associated with an EBV above the lower limit of detection, although with wider confidence intervals.
Incidence of and factors associated with PTLD among all recipients
Among the 2642 recipients included in the cohort, PTLD was identified in 79 (3%) (incidence rate 7.0/1000 personyears of follow-up (PYFU) (95% CI 5.5-8.6) during a median follow-up of 3.5 years [interquartile range (IQR) 1.2-6.7] (Fig. 1) . The vast majority of the cases developed PTLD within 2 years of transplantation [1.8% (95% CI 1.3-2.4) at 12 months; 2.4% (95% CI 1.7-3.0) at 24 months] (Fig. 2b) . Characteristics of recipients with PTLD according to certainty of the diagnosis are presented in Table 2 . The majority of those developing PTLD were males (70%), median age at transplantation was 39.1 (IQR 11.6-57.9), and half of the cases (n = 41) were definite PTLD.
Among the 331 with EBV DNAemia, 16.2% (95% CI 12.1-20.3) developed PTLD 52 weeks after first positive EBV DNA whereas an additional seven (2%) received preemptive rituximab in relation to EBV DNAemia. Analyses of risk of PTLD were repeated testing a wide variety of laboratory parameters. In sensitivity analyses, hemoglobin, thrombocytes and CRP were associated with PTLD, and were, therefore, added to our multivariate model. Similar to the results above, after adjustment, low age [2.87 (1.31-6.29)] was more whereas female gender [0.61 (0.37-1.00)] and low-risk EBV serostatus were less associated with PTLD. Also, as above, a negative EBV DNA was less associated with ] whereas the association between a high EBV DNA (> 5000 copies/ mL) compared to a positive EBV DNA at the lower limit of detection and PTLD was weaker [3.59 (0.97-13.35 . Similar results were seen for EBV DNAemia above the limit of detection, although the test for interaction was no longer statistically significant (p = 0.19). Risk of PTLD among HSCT was assessed adjusting for additional risk factors, such as T-cell-depleting treatment, acute GvHD and donor relation (related vs. unrelated) in addition to the factors included in the main analyses. After adjustment, there was no longer an association between any of the factors from the main analyses and PTLD [a negative vs. positive EBV DNA at the lower limit of detection: aHR 0.45 (95% CI 0.13-1.56)], younger age: 1.40 (0.39-5.05), female gender: 0.75 (0.33-1.72), low-risk EBV serostatus: 0.52 (0.15-1.84). There was a (31) 3 (75) 7 (78) 7 (22) 10 (84) 
Sensitivity and specificity of EBV DNA to predict PTLD among those measured for EBV DNA
Among those with a measurement of EBV DNA (Fig. 1) , ROC plots demonstrated that an EBV DNAemia had an area under the curve (AUC) of 66% (95% CI 60-72%) for identifying recipients with subsequent PTLD, demonstrating a sensitivity and specificity of 47 and 85%, respectively (Table 3) . Furthermore, positive and negative predictive values were 12.5 and 97.2%, respectively. Increasing viral load cut-off values to higher levels did not improve AUC. When relevant clinical information including gender, age, year of transplantation, transplant type, number of transplants, and high-risk EBV serostatus were included in addition to EBV DNAemia (full model) to the ROC, AUC increased to 72% (95% CI 66-78%). Considering SOT separately, AUC of the Definite PTLD = biopsy-confirmed according to WHO criteria 14; probable PTLD = significant lymphadenopathy (or other end-organ disease) with EBV DNAemia with the absence of another cause; possible PTLD = relevant EBV-related symptoms and EBV DNAemia without evidence of probable or proven disease IQR interquartile range, HSCT hematopoietic stem cell transplantation, CNS central nervous system, GI gastrointestinal, N.A non-applicable a Regular screening with EBV DNA was introduced in 2010 for solid organ recipients (SOT) whereas HSCT recipients had regular screening in the entire study period b Sites of PTLD were determined by either biopsy specimens or imaging, such as FDG PET/CT scans, N = 32; definite = 27; probable = 4; possible = 1 c Definite PTLD cases were diagnosed appropriately before initiating treatment ROC for EBV DNA alone for predicting PTLD was 72% (95% CI 64-79%) increasing to 82% (76-88%) in the full model. AUC increased to 83% (75-90%) when adjusting for the laboratory parameters hemoglobin, thrombocytes, and CRP (Fig. 3a) .
Among HSCT, AUC of the ROC for EBV DNA alone for predicting PTLD was 59% (95% CI 51-68%), increasing to 77% (70-84%) in the full model. This increased further when adjusting for the laboratory parameters to 84% (CI 79-89%). Adding additional risk factors of T-cell-depleting treatment, acute GvHD, and donor relation increased AUC to 85% (78-91%) (Fig. 3b) .
Sensitivity analyses
Sensitivity analysis excluding EBV PCR results performed within 7 days from CT and PET/CT scans were performed to exclude the EBV DNAemia which was detected as part of the diagnostic procedure in relation to PTLD diagnosis. These results were similar to the main results although with wider confidence intervals.
Repeating analysis including only definite PTLD also led to similar results as the main results, although with wider confidence intervals given the smaller number of cases. The AUC of a positive EBV DNA for predicting PTLD was higher compared to when including all PTLD cases; 68% (60-76%) for EBV DNA alone increasing to 82% (95% CI 76-89%) in the full model.
Discussion
This cohort study shows that an EBV DNAemia developed after SOT or HSCT carried an increased risk of progressing to PTLD even after adjusting for relevant factors such as demographics, type of transplantation, serostatus for EBV, and laboratory values at time of transplantation. However, less than 1 out of 5 of recipients with EBV DNAemia progressed to develop PTLD 1 year after first positive EBV DNA and the ability of an EBV DNAemia to predict PTLD had low sensitivity. Conversely, when EBV DNAemia was assessed together with other clinically relevant information, such as gender, age, transplant year, transplant type, number of transplantations, and high-risk EBV serostatus, the AUC for the ROC increased significantly and we were better able to identify those with PTLD. Our prognostic model performed particularly well among SOT, and among HSCT when including further risk factors such as T-cell-depleting treatment, with AUC of the ROC above 80% in both groups.
Risk factors of PTLD determined in the present study were generally consistent with what have been reported previously, namely young males with high-risk donor-recipient EBV serostatus among SOT (Green and Michaels 2013; Morton et al. 2014; Schaffer et al. 2011 ) and T-cell-depleting treatment and increased risk in more recent years among HSCT (Landgren et al. 2009; Meijer et al. 2002) . In fact, T-cell-depleting treatment led to a tenfold increased risk of progressing to PTLD and this treatment modality seemed to have a much higher importance in regard of predicting those with PTLD compared to EBV DNAemia.
Although previous reports support our finding in regard of the low sensitivity of an EBV DNAemia alone to predict PTLD among SOT (Bamoulid et al. 2013; Hocker et al. 2013; Holman et al. 2012) and HSCT (Wagner et al. 2004; van Esser et al. 2001) , EBV DNA screening is still a widely recommended and used tool (Styczynski et al. 2009; SanJuan et al. 2015) . The test is minimally invasive, applicable to most centers and currently the only known biomarker to be used in the follow-up after SOT or HSCT to early diagnose PTLD. To our knowledge, our study is the first to propose a model where, if used in this context, information routinely available in addition to EBV DNA screening could be used to better predict those who would most likely develop PTLD and thus identify those who would benefit from early management or more intensive follow-up. External validation of our findings in a separate cohort is needed and upon good performance, this model could have clinical implications and be used as part of routine management of transplant recipients in the first year after transplantation.
Our results should be seen in the light of their limitations. EBV DNA measurements included both those performed as part of the screening protocol and as part of a diagnostic procedure and thus, differed between patient groups and over calendar time. However, we performed several sensitivity analyses to address this, including excluding EBV PCR results performed in connection with CT and PET/CT scans to exclude those not performed as part of screening, which showed similar results, and adds strength to our findings. Further, all EBV DNA results were lagged to 28 days to reduce the impact of reverse causality. Excluding recipients transplanted prior to 2010 led to similar results as our main findings, although with notably less precision. To address the heterogeneity of our patient population we stratified analyses by type of transplant and could confirm the differences in both SOT and HSCT recipients. We also performed sensitivity analyses. Our classification of PTLD included both probable and possible cases, possibly including other disease entities than PTLD. Sensitivity analyses including only definite PTLD showed similar results. Probable and possible cases largely depended on EBV DNA results which could potentially increase the strength of association between EBV DNAemia and PTLD development, but our data do not support this bias as EBV DNAemia was a poor predictor when assessed alone.
Conversely, use of pre-emptive rituximab or reduction of immunosuppression could prevent potential PTLD development and thus underestimate the diagnostic performance of detected EBV DNA. However, by including the definition of possible and probable PTLD, we believe that we likely captured most of those cases who if left untreated would likely progress to fulminant PTLD.
The major strengths of this study include the size and the heterogeneous transplant recipients who were all transplanted at a tertiary hospital and closely monitored during the first year following transplantation. Furthermore, we ensured a comprehensive clinical review across the entire cohort for ascertainment of PTLD including definite PTLD, ascertained independently of EBV DNA results.
In summary, this study provides novel information of the clinical course of EBV DNAemia following SOT or HSCT and the clinical value of this test for identifying recipients with risk of subsequent PTLD. Based on our results, testing for EBV DNAemia has a low clinical value and cannot be recommended alone. However, including relevant clinical characteristics such as gender, age, year and type of transplantation, number of transplantations and high-risk EBV serological status, in addition to EBV DNAemia as proposed in this study, increased the sensitivity of this test, and may provide important information in the clinical management of transplant recipients.
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